Keebeck Wealth Management
ABBV icon

Keebeck Wealth Management’s AbbVie ABBV Stock Holding History

Keebeck Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.71M Sell
21,839
-166
-0.8% -$42.6K 0.56% 41
2026
Q2 		$5.54M Buy
22,005
+1,401
+7% +$301K 0.54% 44
2026
Q1 		$4.48M Sell
20,604
-3,324
-14% -$737K 0.5% 49
2025
Q4 		$5.47M Sell
23,928
-623
-3% -$142K 0.63% 34
2025
Q3 		$5.68M Sell
24,551
-57
-0.2% -$11.6K 0.67% 38
2025
Q2 		$4.57M Sell
24,608
-548
-2% -$102K 0.6% 46
2025
Q1 		$5.27M Buy
25,156
+148
+0.6% +$28.8K 0.78% 34
2024
Q4 		$4.44M Sell
25,008
-141
-0.6% -$25.9K 0.64% 44
2024
Q3 		$4.97M Sell
25,149
-234
-0.9% -$43.7K 0.72% 40
2024
Q2 		$4.35M Buy
25,383
+8,711
+52% +$1.44M 0.64% 41
2024
Q1 		$3.04M Buy
16,672
+13,380
+406% +$2.31M 0.45% 63
2023
Q4 		$510K Buy
3,292
+77
+2% +$11.2K 0.08% 174
2023
Q3 		$479K Buy
3,215
+168
+6% +$24.7K 0.08% 177
2023
Q2 		$411K Buy
3,047
+35
+1% +$5.13K 0.06% 193
2023
Q1 		$480K Sell
3,012
-716
-19% -$109K 0.08% 165
2022
Q4 		$602K Buy
3,728
+22
+0.6% +$3.37K 0.11% 140
2022
Q3 		$497K Buy
3,706
+8
+0.2% +$1.15K 0.1% 150
2022
Q2 		$566K Buy
3,698
+7
+0.2% +$1.07K 0.11% 146
2022
Q1 		$598K Buy
3,691
+8
+0.2% +$1.16K 0.1% 150
2021
Q4 		$499K Buy
3,683
+312
+9% +$36.9K 0.09% 149
2021
Q3 		$364K Buy
3,371
+8
+0.2% +$914 0.07% 160
2021
Q2 		$379K Sell
3,363
-16,896
-83% -$1.9M 0.05% 188
2021
Q1 		$2.19M Sell
20,259
-114
-0.6% -$12.2K 0.34% 59
2020
Q4 		$2.18M Buy
20,373
+11
+0.1% +$1.06K 0.38% 55
2020
Q3 		$1.78M Buy
20,362
+904
+5% +$85.1K 0.37% 54
2020
Q2 		$1.91M Buy
+19,458
New +$1.71M 0.6% 38
2020
Q1 		– Sell
-2,458
Closed -$217K – 140
2019
Q4 		$217K Buy
+2,458
New +$204K 0.07% 136

Other funds holding ABBV

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Keebeck Wealth Management's ABBV Position: Q3 2026 in Review

Keebeck Wealth Management reduced its AbbVie (ABBV) stake by 0.75% in Q3 2026, selling an estimated $42.6K and leaving 21,839 shares worth $5.71M. The position accounts for 0.56% of the portfolio, ranked #41.

Keebeck Wealth Management first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. 3,701 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Keebeck Wealth Management held 21,839 shares of AbbVie worth $5.71M as of Q3 2026.
  • Keebeck Wealth Management sold 166 AbbVie shares in Q3 2026, an estimated $42.6K.
  • AbbVie made up 0.56% of Keebeck Wealth Management's portfolio in Q3 2026, its #41 holding.
  • Keebeck Wealth Management first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • 3,701 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Keebeck Wealth Management's 13F filing for Q3 2026, filed 12 Nov 2026.